查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
In Silico 药物发现市场 - 2017-2027 年全球行业规模、份额、趋势、机会和预测，按组件、工作流程、软件类型、技术、治疗领域、最终用户、公司和地区细分
市场调查报告书
商品编码
1321044

In Silico 药物发现市场 - 2017-2027 年全球行业规模、份额、趋势、机会和预测，按组件、工作流程、软件类型、技术、治疗领域、最终用户、公司和地区细分

In Silico Drug Discovery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Workflow, By Software Type, By Technology, By Therapeutic Area, By End User, By Company and By Region
出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

预计在 2023 年至 2027 年的预测期内，全球计算机模拟药物发现市场将出现令人印象深刻的增长。主要因素包括各种疾病发病率的增加、基于云的应用程序的使用增加以及技术的广泛发展，这些都抑制了市场的增长。如今，计算机方法正在成为药物发现过程的重要组成部分。这主要是因为它对整个药物开发轨蹟的影响，识别和发现新的潜在药物，同时大幅减少成本和时间。支持市场增长的其他因素包括广泛的研究和开发、各种疾病的流行、大量的临床试验、越来越重视减少医疗错误和再入院率、各种投资、公司之间的合作数量不断增加以及药物发现数据量。

基于云的应用程序的采用不断增加

云应用程序的使用不断增加，推动了计算机模拟药物发现市场的增长。云计算使製药研究人员能够使用几乎无限的计算资源，从而允许他们扩大或缩小其计算环境。云计算不仅提高了整体生产力，还最大限度地减少了临床失败的机会。例如，2020 年，布里斯託大学的研究人员声称使用基于云的解决方案成功解释了一种名为 ADDomer 的潜在预防性干预措施的结构。

技术进步支撑市场

计算生物学领域的快速技术进步正在推动全球计算机模拟药物发现市场的增长。计算技术在新型药物化合物的开发中非常有效。技术的进步正在简化测序的各个步骤，因此获得的结果更快、更准确。例如，2021 年，辉瑞公司 (Pfizer Inc.) 和亚马逊网络服务 (AWS) 已批准合作开发基于云的新型技术，这些技术可以使临床试验中新药的研究、製造和传播方式现代化。同样，2022 年，Insilico Medicine 和苏黎世大学合作，利用 Insilico 的动态人工智能技术来发现新的胱氨酸病治疗方法。

增加投资和合作

随着各种疾病发生率的增加，对药物发现和开发的大量投资正在推动市场的增长。例如，2021年，根据美国药物研究和製造商协会（PhRMA）发布的一份报告，生物製药公司在过去十年中在研发方面的投资超过一万亿美元，其中2020年创下了创纪录的一年，当时PhRMA成员行业仅投资约910亿美元。此外，人工智能初创企业与领先研究中心建立的合作伙伴关係越来越多，可能会提供替代指标。例如，2019 年，作为 2017 年与 GSK 开始的 3300 万英镑合作伙伴关係的一部分，Exscientia 提供了一种针对慢性阻塞性肺疾病治疗的先导分子。

市场细分

全球计算机模拟药物发现市场分为组件、工作流程、软件类型、技术、治疗领域、最终用户和公司。根据组件，市场分为软件、软件即服务和咨询即服务。根据工作流程，市场分为发现、临床前测试和临床试验。基于这一发现，市场进一步细分为目标识别、目标验证和先导化合物发现。根据软件类型，市场分为分子建模和从头药物设计软件以及药效团建模软件。根据技术，市场分为人工智能、图形处理单元等。根据治疗领域，市场分为人类免疫缺陷病毒（HIV）、传染病、代谢性疾病、肿瘤疾病等。根据最终用户，市场分为生物技术和製药公司、合同研究组织、学术和研究组织等。就国家而言，由于美国广泛的技术发展，预计在预测期内美国将成为一个利润丰厚的市场。

市场参与者

阿拉根生命科学列兵。 Ltd. (GVK Biosciences Pvt. Ltd.)、Curia Global, Inc. (奥尔巴尼分子研究公司)、Charles River Laboratories International, Inc.、ChemicalComputing Group ULC。 (CCG)、Collaborative Drug Discovery Inc. (CDD)、e-therapeutics plc.、Dassault Systemes SE、Insilico Medicine, Inc.、Numerate, Inc. 和 Schrodinger, Inc. 是市场上运营的一些领先公司。

可用的定制

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供定制服务。该报告可以使用以下自定义选项：

公司信息

  • 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：COVID-19 对全球计算机模拟药物发现市场的影响

第 5 章：客户之声

第 6 章：全球计算机模拟药物发现市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按组件（软件、软件即服务、咨询即服务）
    • 按工作流程（发现、临床前测试、临床试验）
    • 按软件类型（分子建模和从头药物设计软件、药效团建模软件）
    • 按技术（人工智能、图形处理单元、其他）
    • 按治疗领域（人类免疫缺陷病毒 (HIV)、传染病、代谢紊乱、肿瘤疾病、其他）
    • 按最终用户（生物技术和製药公司、合同研究组织、学术和研究组织、其他）
    • 按公司划分 (2021)
    • 按地区
  • 市场地图

第 7 章：北美计算机模拟药物发现市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按组件（软件、软件即服务、咨询即服务）
    • 按工作流程（发现、临床前测试、临床试验）
    • 按软件类型（分子建模和从头药物设计软件、药效团建模软件）
    • 按技术（人工智能、图形处理单元、其他）
    • 按治疗领域（人类免疫缺陷病毒 (HIV)、传染病、代谢紊乱、肿瘤疾病、其他）
    • 按最终用户（生物技术和製药公司、合同研究组织、学术和研究组织、其他）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 8 章：欧洲计算机模拟药物发现市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按组件（软件、软件即服务、咨询即服务）
    • 按工作流程（发现、临床前测试、临床试验）
    • 按软件类型（分子建模和从头药物设计软件、药效团建模软件）
    • 按技术（人工智能、图形处理单元、其他）
    • 按治疗领域（人类免疫缺陷病毒 (HIV)、传染病、代谢紊乱、肿瘤疾病、其他）
    • 按最终用户（生物技术和製药公司、合同研究组织、学术和研究组织、其他）
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第 9 章：亚太地区计算机模拟药物发现市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按组件（软件、软件即服务、咨询即服务）
    • 按工作流程（发现、临床前测试、临床试验）
    • 按软件类型（分子建模和从头药物设计软件、药效团建模软件）
    • 按技术（人工智能、图形处理单元、其他）
    • 按治疗领域（人类免疫缺陷病毒 (HIV)、传染病、代谢紊乱、肿瘤疾病、其他）
    • 按最终用户（生物技术和製药公司、合同研究组织、学术和研究组织、其他）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 10 章：南美洲计算机模拟药物发现市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按组件（软件、软件即服务、咨询即服务）
    • 按工作流程（发现、临床前测试、临床试验）
    • 按软件类型（分子建模和从头药物设计软件、药效团建模软件）
    • 按技术（人工智能、图形处理单元、其他）
    • 按治疗领域（人类免疫缺陷病毒 (HIV)、传染病、代谢紊乱、肿瘤疾病、其他）
    • 按最终用户（生物技术和製药公司、合同研究组织、学术和研究组织、其他）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章：中东和非洲计算机模拟药物发现市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按组件（软件、软件即服务、咨询即服务）
    • 按工作流程（发现、临床前测试、临床试验）
    • 按软件类型（分子建模和从头药物设计软件、药效团建模软件）
    • 按技术（人工智能、图形处理单元、其他）
    • 按治疗领域（人类免疫缺陷病毒 (HIV)、传染病、代谢紊乱、肿瘤疾病、其他）
    • 按最终用户（生物技术和製药公司、合同研究组织、学术和研究组织、其他）
    • 按国家/地区
  • MEA：国家分析
    • 南非计算机模拟药物发现
    • 沙特阿拉伯计算机模拟药物发现
    • 阿联酋计算机模拟药物发现
    • 土耳其计算机模拟药物发现
    • 埃及计算机模拟药物发现

第 12 章：市场动态

  • 司机
  • 挑战

第 13 章：市场趋势与发展

第14章：竞争格局

  • 阿拉根生命科学列兵。有限公司（GVK Biosciences Pvt. Ltd.）
  • Curia Global, Inc.（奥尔巴尼分子研究公司）
  • 查尔斯河实验室国际有限公司
  • 化学计算组 ULC。 （CCG）
  • 协作药物发现公司（CDD）
  • 电子治疗公司
  • 达索系统公司
  • 英科智能医药有限公司
  • 数字公司
  • 薛定谔公司

第 15 章：战略建议

简介目录
Product Code: 13007

The global in silico drug discovery market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include growing incidences of various diseases, rising use of cloud-based applications, and extensive development in technology, which are curbing the market's growth. Nowadays, in silico methodologies are becoming an essential part of the drug discovery process. This is primarily because of the impact on the whole drug development trajectory, identifying and discovering new potential drugs with a substantial reduction in cost and time. The other factors supporting the market's growth are the extensive research and development, prevalence of various diseases, large number of clinical trials, rising emphasis on reduction in medical errors and readmission rates, various investments, the growing number of collaborations between companies, and rise in the volume of drug discovery data.

Rising Adoption of Cloud-Based Applications

The increasing use of cloud applications is fueling the growth of the in-silico drug discovery market. Cloud computing gives access to pharmaceutical researchers to use virtually infinite computational resources, permitting them to scale up or down their computing environment. Cloud computing has not only enhanced overall productivity but also minimized the chances of clinical failure. For instance, in 2020, researchers at the University of Bristol alleged to have used cloud-based solutions to successfully interpret the structure of a potential preventive intervention called ADDomer.

Technological Advancements Support the Market

Rapid technological advancements in the field of computational biology are bolstering the growth of the in-silico drug discovery market globally. Computational techniques are quite effective in the development of novel pharmaceutical compounds. The advancement in technologies is simplifying the various steps in sequencing, due to which the results obtained are faster and more accurate. For instance, in 2021, Pfizer Inc. and Amazon Web Services (AWS) have approved to work together on developing novel cloud-based technologies that could modernize how new medications are studied, manufactured, and disseminated for clinical trials. Similarly, in 2022, Insilico Medicine and the University of Zurich collaborated to leverage Insilico's dynamic AI technology to discover new cystinosis treatments.

Increasing Investments and Collaborations

Heavy investments in drug discovery and development with rising occurrences of various diseases are propelling the growth of the market. For instance, in 2021, as per a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA), biopharmaceutical companies invested more than a trillion dollars in R&D in the last ten years, including a record year in 2020, when PhRMA member industries alone invested approximately 91 billion USD. Furthermore, the increasing number of partnerships that AI start-ups have with leading research centers may offer an alternative metric. For instance, in 2019, as a part of a £33 million partnership with GSK that commenced in 2017, Exscientia delivered a lead molecule targeted at the treatment of chronic obstructive pulmonary disease.

Market Segmentation

The global in silico drug discovery market is segmented into components, workflow, software type, technology, therapeutic area, end user, and company. Based on components, the market is divided into software, software-as-a-service, and consultancy-as-a-service. Based on workflow, the market is divided into discovery, pre-clinical tests, and clinical trials. Based on the discovery, the market is further segmented into target identification, target validation, and lead discovery. Based on software type, the market is segmented into molecular modeling & de novo drug design software and pharmacophore modeling software. Based on technology, the market is segmented into artificial intelligence, graphics processing unit, and others. Based on therapeutic area, the market is segmented into human immunodeficiency virus (HIV), infectious diseases, metabolic disorders, oncology disorders, and others. Based on end users, the market is divided into biotechnology & pharmaceutical companies, contract research organizations, academic & research organizations, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the extensive technology development in the country.

Market Players

Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.), Curia Global, Inc. (Albany Molecular Research Inc.), Charles River Laboratories International, Inc., Chemical Computing Group ULC. (CCG), Collaborative Drug Discovery Inc. (CDD), e-therapeutics plc., Dassault Systemes SE, Insilico Medicine, Inc., Numerate, Inc., and Schrodinger, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global in silico drug discovery market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

In Silico Drug Discovery Market, By Component:

  • Software
  • Software-as-a-Service
  • Consultancy-as-a-Service

In Silico Drug Discovery Market, By Workflow:

  • Discovery
    • Target Identification
    • Target Validation
    • Lead Discovery
  • Pre-Clinical Tests
  • Clinical Trials

In Silico Drug Discovery Market, By Software Type:

  • Molecular Modeling & De Novo Drug Design Software
  • Pharmacophore Modeling Software

In Silico Drug Discovery Market, By Technology:

  • Artificial Intelligence
  • Graphics Processing Unit
  • Others

In Silico Drug Discovery Market, By Therapeutic Area:

  • Human Immunodeficiency Virus (HIV)
  • Infectious Diseases
  • Metabolic Disorders
  • Oncology Disorders
  • Others

In Silico Drug Discovery Market, By End User:

  • Biotechnology & Pharmaceutical Companies
  • Contract Research Organizations
  • Academic & Research Organizations
  • Others

In Silico Drug Discovery Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global In Silico Drug Discovery Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global In Silico Drug Discovery Market

5. Voice of Customer

6. Global In Silico Drug Discovery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 6.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 6.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 6.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 6.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 6.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 6.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 6.2.7. By Company (2021)
    • 6.2.8. By Region
  • 6.3. Market Map

7. North America In Silico Drug Discovery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 7.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 7.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 7.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 7.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 7.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 7.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 7.2.7. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States In Silico Drug Discovery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Software Type
        • 7.3.1.2.4. By Technology
        • 7.3.1.2.5. By Therapeutic Area
        • 7.3.1.2.6. By End User
    • 7.3.2. Canada In Silico Drug Discovery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Software Type
        • 7.3.2.2.4. By Technology
        • 7.3.2.2.5. By Therapeutic Area
        • 7.3.2.2.6. By End User
    • 7.3.3. Mexico In Silico Drug Discovery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Software Type
        • 7.3.3.2.4. By Technology
        • 7.3.3.2.5. By Therapeutic Area
        • 7.3.3.2.6. By End User

8. Europe In Silico Drug Discovery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 8.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 8.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 8.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 8.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 8.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 8.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France In Silico Drug Discovery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Software Type
        • 8.3.1.2.4. By Technology
        • 8.3.1.2.5. By Therapeutic Area
        • 8.3.1.2.6. By End User
    • 8.3.2. Germany In Silico Drug Discovery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Software Type
        • 8.3.2.2.4. By Technology
        • 8.3.2.2.5. By Therapeutic Area
        • 8.3.2.2.6. By End User
    • 8.3.3. United Kingdom In Silico Drug Discovery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Software Type
        • 8.3.3.2.4. By Technology
        • 8.3.3.2.5. By Therapeutic Area
        • 8.3.3.2.6. By End User
    • 8.3.4. Italy In Silico Drug Discovery Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Software Type
        • 8.3.4.2.4. By Technology
        • 8.3.4.2.5. By Therapeutic Area
        • 8.3.4.2.6. By End User
    • 8.3.5. Spain In Silico Drug Discovery Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Software Type
        • 8.3.5.2.4. By Technology
        • 8.3.5.2.5. By Therapeutic Area
        • 8.3.5.2.6. By End User

9. Asia-Pacific In Silico Drug Discovery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 9.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 9.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 9.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 9.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 9.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 9.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 9.2.7. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China In Silico Drug Discovery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Software Type
        • 9.3.1.2.4. By Technology
        • 9.3.1.2.5. By Therapeutic Area
        • 9.3.1.2.6. By End User
    • 9.3.2. India In Silico Drug Discovery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Software Type
        • 9.3.2.2.4. By Technology
        • 9.3.2.2.5. By Therapeutic Area
        • 9.3.2.2.6. By End User
    • 9.3.3. Japan In Silico Drug Discovery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Software Type
        • 9.3.3.2.4. By Technology
        • 9.3.3.2.5. By Therapeutic Area
        • 9.3.3.2.6. By End User
    • 9.3.4. South Korea In Silico Drug Discovery Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Workflow
        • 9.3.4.2.3. By Software Type
        • 9.3.4.2.4. By Technology
        • 9.3.4.2.5. By Therapeutic Area
        • 9.3.4.2.6. By End User
    • 9.3.5. Australia In Silico Drug Discovery Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Workflow
        • 9.3.5.2.3. By Software Type
        • 9.3.5.2.4. By Technology
        • 9.3.5.2.5. By Therapeutic Area
        • 9.3.5.2.6. By End User

10. South America In Silico Drug Discovery Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 10.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 10.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 10.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 10.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 10.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 10.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil In Silico Drug Discovery Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Software Type
        • 10.3.1.2.4. By Technology
        • 10.3.1.2.5. By Therapeutic Area
        • 10.3.1.2.6. By End User
    • 10.3.2. Argentina In Silico Drug Discovery Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Software Type
        • 10.3.2.2.4. By Technology
        • 10.3.2.2.5. By Therapeutic Area
        • 10.3.2.2.6. By End User
    • 10.3.3. Colombia In Silico Drug Discovery Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Software Type
        • 10.3.3.2.4. By Technology
        • 10.3.3.2.5. By Therapeutic Area
        • 10.3.3.2.6. By End User

11. Middle East and Africa In Silico Drug Discovery Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component (Software, Software-as-a-Service, Consultancy-as-a-Service)
    • 11.2.2. By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials)
      • 11.2.2.1. By Discovery (Target Identification, Target Validation, Lead Discovery)
    • 11.2.3. By Software Type (Molecular Modeling & De Novo Drug Design Software, Pharmacophore Modeling Software)
    • 11.2.4. By Technology (Artificial Intelligence, Graphics Processing Unit, Others)
    • 11.2.5. By Therapeutic Area (Human Immunodeficiency Virus (HIV), Infectious Diseases, Metabolic Disorders, Oncology Disorders, Others)
    • 11.2.6. By End User (Biotechnology & Pharmaceutical Companies, Contract Research Organizations, Academic & Research Organizations, Others)
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa In Silico Drug Discovery Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Workflow
        • 11.3.1.2.3. By Software Type
        • 11.3.1.2.4. By Technology
        • 11.3.1.2.5. By Therapeutic Area
        • 11.3.1.2.6. By End User
    • 11.3.2. Saudi Arabia In Silico Drug Discovery Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Workflow
        • 11.3.2.2.3. By Software Type
        • 11.3.2.2.4. By Technology
        • 11.3.2.2.5. By Therapeutic Area
        • 11.3.2.2.6. By End User
    • 11.3.3. UAE In Silico Drug Discovery Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Workflow
        • 11.3.3.2.3. By Software Type
        • 11.3.3.2.4. By Technology
        • 11.3.3.2.5. By Therapeutic Area
        • 11.3.3.2.6. By End User
    • 11.3.4. Turkey In Silico Drug Discovery Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Component
        • 11.3.4.2.2. By Workflow
        • 11.3.4.2.3. By Software Type
        • 11.3.4.2.4. By Technology
        • 11.3.4.2.5. By Therapeutic Area
        • 11.3.4.2.6. By End User
    • 11.3.5. Egypt In Silico Drug Discovery Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Component
        • 11.3.5.2.2. By Workflow
        • 11.3.5.2.3. By Software Type
        • 11.3.5.2.4. By Technology
        • 11.3.5.2.5. By Therapeutic Area
        • 11.3.5.2.6. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.)
  • 14.2. Curia Global, Inc. (Albany Molecular Research Inc.)
  • 14.3. Charles River Laboratories International, Inc.
  • 14.4. Chemical Computing Group ULC. (CCG)
  • 14.5. Collaborative Drug Discovery Inc. (CDD)
  • 14.6. e-therapeutics plc.
  • 14.7. Dassault Systemes SE
  • 14.8. Insilico Medicine, Inc.
  • 14.9. Numerate, Inc.
  • 14.10. Schrodinger, Inc.

15. Strategic Recommendations